NASDAQ:JNCE - Jounce Therapeutics Stock Price, Forecast & News

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

Jounce Therapeutics Inc (NASDAQ:JNCE) posted its quarterly earnings results on Thursday, February, 27th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.28) by $0.40. Jounce Therapeutics had a return on equity of 64.54% and a net margin of 46.11%. View Jounce Therapeutics' Earnings History.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Jounce Therapeutics.

Press coverage about JNCE stock has been trending extremely negative on Friday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Jounce Therapeutics earned a daily sentiment score of -4.4 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Jounce Therapeutics.

Jounce Therapeutics saw a increase in short interest in the month of February. As of February 14th, there was short interest totalling 2,320,000 shares, an increase of 5.5% from the January 30th total of 2,200,000 shares. Based on an average daily volume of 774,700 shares, the days-to-cover ratio is currently 3.0 days. Approximately 15.0% of the company's stock are short sold. View Jounce Therapeutics' Current Options Chain.

Some companies that are related to Jounce Therapeutics include Cellectis (CLLS), Vericel (VCEL), AVITA MED LTD/S (RCEL), Rubius Therapeutics (RUBY), Osiris Therapeutics (OSIR), AVITA MED LTD/S (AVMXY), Proteon Therapeutics (PRTO), Atara Biotherapeutics (ATRA), GENFIT S A/ADR (GNFT), Avrobio (AVRO), MeiraGTx (MGTX), Replimune Group (REPL), Prevail Therapeutics (PRVL), Aptose Biosciences (APTO) and Nantkwest (NK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Jounce Therapeutics investors own include Exelixis (EXEL), Teva Pharmaceutical Industries (TEVA), Crispr Therapeutics (CRSP), Amarin (AMRN), Neurocrine Biosciences (NBIX), Nektar Therapeutics (NKTR), Intellia Therapeutics (NTLA), Progenics Pharmaceuticals (PGNX), Advanced Micro Devices (AMD) and Sorrento Therapeutics (SRNE).

(JNCE) raised $76 million in an initial public offering (IPO) on Friday, January 27th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

Jounce Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (3.73%), Acadian Asset Management LLC (2.04%), Marshall Wace LLP (1.43%), Renaissance Technologies LLC (1.23%), State Street Corp (1.23%) and Geode Capital Management LLC (0.78%). Company insiders that own Jounce Therapeutics stock include Barbara Gayle Duncan, Elizabeth Trehu, Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin and Richard /Ca/ Murray. View Institutional Ownership Trends for Jounce Therapeutics.

JNCE stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio, Prudential Financial Inc., Bank of America Corp DE, Goldman Sachs Group Inc., State Street Corp, Bailard Inc., Meeder Asset Management Inc. and Tower Research Capital LLC TRC . Company insiders that have sold Jounce Therapeutics company stock in the last year include Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin and Richard /Ca/ Murray. View Insider Buying and Selling for Jounce Therapeutics.

JNCE stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Marshall Wace LLP, Renaissance Technologies LLC, Acadian Asset Management LLC, Point72 Asset Management L.P., Bank of New York Mellon Corp, Charles Schwab Investment Management Inc. and Oxford Asset Management LLP. View Insider Buying and Selling for Jounce Therapeutics.

Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of JNCE stock can currently be purchased for approximately $4.55.

Jounce Therapeutics has a market capitalization of $151.19 million and generates $65.20 million in revenue each year. The company earns $-27,380,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Jounce Therapeutics employs 115 workers across the globe.View Additional Information About Jounce Therapeutics.

The official website for Jounce Therapeutics is http://www.jouncetx.com/.

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840.